Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease globally, and endoscopic sleeve gastroplasty (ESG) has emerged as a feasible and effective intervention for managing obesity. A systematic review and meta-analysis of four observational studies, including 175 patients, evaluated the impact of ESG on NAFLD and metabolic parameters 12 months post-procedure. The analysis revealed significant improvements in liver health, with reductions in hepatic steatosis index, NAFLD fibrosis score, and ALT levels. Additionally, patients experienced substantial weight loss, with a 17.28% decrease in total weight loss (TWL) and a 47.97% reduction in excess weight loss (EWL).

The study also found that ESG led to a significant reduction in body mass index (BMI) by 6.31 kg/m² and a decrease in HbA1c levels by 0.51%, indicating improved metabolic control in patients with NAFLD. These findings suggest that ESG not only aids in weight loss but also positively impacts liver function and metabolic health in individuals with NAFLD, making it a promising treatment option for this widespread condition.

Reference: Nunes BCM, de Moura DTH, Kum AST, et al. Impact of Endoscopic Sleeve Gastroplasty in Non-alcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis. Obes Surg. 2023 Sep;33(9):2917-2926. doi: 10.1007/s11695-023-06747-4. Epub 2023 Aug 4. PMID: 37537506.